Organovo Operating Income vs Research Development Analysis

ONVO Stock

USD 0.43 0.01 2.38%

Organovo Holdings financial indicator trend analysis is much more than just breaking down Organovo Holdings prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Organovo Holdings is a good investment. Please check the relationship between Organovo Holdings Operating Income and its Research Development accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organovo Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Organovo Stock, please use our How to Invest in Organovo Holdings guide.

Operating Income vs Research Development

Operating Income vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Organovo Holdings Operating Income account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between Organovo Holdings' Operating Income and Research Development is -0.93. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Research Development in the same time period over historical financial statements of Organovo Holdings, assuming nothing else is changed. The correlation between historical values of Organovo Holdings' Operating Income and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Organovo Holdings are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Operating Income i.e., Organovo Holdings' Operating Income and Research Development go up and down completely randomly.

Correlation Coefficient

-0.93

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Organovo Holdings operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Organovo Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Research Development

Most indicators from Organovo Holdings' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Organovo Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organovo Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Organovo Stock, please use our How to Invest in Organovo Holdings guide.At this time, Organovo Holdings' Selling General Administrative is very stable compared to the past year. As of the 28th of November 2024, Sales General And Administrative To Revenue is likely to grow to 92.90, while Tax Provision is likely to drop 1,710.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	142K	293K	5.5M	4.2M
Research Development	3.3M	8.9M	5.5M	7.4M

Cost Of Revenue Research Development

Organovo Holdings fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Non Current Assets Total	Non Currrent Assets Other	Net Receivables	Non Current Liabilities Total	Inventory	Property Plant And Equipment Gross	Other Current Liab	Property Plant And Equipment Net	Current Deferred Revenue	Other Assets
Total Assets		0.07	0.97	-1.0	-0.09	0.63	1.0	1.0	0.6	-0.12	0.55	0.33	0.09	1.0	0.69	0.34	0.55	0.01	0.48	0.14	0.2	0.39	-0.51	0.53	-0.33	-0.26
Total Current Liabilities	0.07		-0.16	-0.07	0.24	0.19	0.06	0.06	0.18	-0.44	-0.11	-0.26	0.99	0.07	0.23	-0.32	0.0	-0.22	0.15	-0.19	0.27	-0.01	0.35	0.02	0.26	-0.32
Total Stockholder Equity	0.97	-0.16		-0.97	-0.13	0.58	0.97	0.97	0.56	-0.04	0.56	0.37	-0.14	0.97	0.64	0.39	0.53	0.05	0.44	0.16	0.13	0.37	-0.58	0.51	-0.39	-0.19
Net Debt	-1.0	-0.07	-0.97		0.02	-0.61	-1.0	-1.0	-0.63	0.19	-0.51	-0.27	-0.08	-1.0	-0.71	-0.29	-0.47	0.03	-0.46	-0.06	-0.18	-0.3	0.47	-0.46	0.33	0.29
Retained Earnings	-0.09	0.24	-0.13	0.02		-0.23	-0.05	-0.05	0.14	-0.89	-0.67	-0.96	0.18	-0.06	0.0	-0.66	-0.5	-0.63	0.03	-0.75	0.15	-0.54	0.81	-0.31	0.33	-0.75
Accounts Payable	0.63	0.19	0.58	-0.61	-0.23		0.62	0.62	0.48	0.0	0.31	0.33	0.2	0.62	0.57	0.09	0.47	-0.18	0.29	0.14	0.09	0.44	-0.48	0.5	-0.33	-0.08
Cash	1.0	0.06	0.97	-1.0	-0.05	0.62		1.0	0.62	-0.16	0.53	0.29	0.07	1.0	0.7	0.3	0.49	-0.01	0.46	0.08	0.17	0.33	-0.49	0.48	-0.34	-0.27
Cash And Short Term Investments	1.0	0.06	0.97	-1.0	-0.05	0.62	1.0		0.62	-0.16	0.53	0.29	0.07	1.0	0.7	0.31	0.5	-0.01	0.46	0.09	0.17	0.33	-0.49	0.48	-0.34	-0.27
Common Stock Total Equity	0.6	0.18	0.56	-0.63	0.14	0.48	0.62	0.62		-0.38	-0.02	0.02	0.16	0.62	0.95	0.19	-0.01	-0.58	0.63	-0.16	0.43	-0.05	-0.12	0.1	-0.12	-0.41
Common Stock Shares Outstanding	-0.12	-0.44	-0.04	0.19	-0.89	0.0	-0.16	-0.16	-0.38		0.49	0.85	-0.37	-0.15	-0.28	0.61	0.43	0.69	-0.21	0.81	-0.31	0.53	-0.65	0.25	-0.25	0.77
Other Current Assets	0.55	-0.11	0.56	-0.51	-0.67	0.31	0.53	0.53	-0.02	0.49		0.75	-0.07	0.53	0.13	0.53	0.51	0.77	0.03	0.45	-0.2	0.35	-0.74	0.28	-0.45	0.51
Other Stockholder Equity	0.33	-0.26	0.37	-0.27	-0.96	0.33	0.29	0.29	0.02	0.85	0.75		-0.2	0.3	0.17	0.75	0.58	0.62	0.09	0.75	-0.12	0.59	-0.88	0.39	-0.4	0.65
Total Liab	0.09	0.99	-0.14	-0.08	0.18	0.2	0.07	0.07	0.16	-0.37	-0.07	-0.2		0.08	0.22	-0.26	0.09	-0.18	0.16	-0.1	0.27	0.08	0.31	0.1	0.26	-0.29
Total Current Assets	1.0	0.07	0.97	-1.0	-0.06	0.62	1.0	1.0	0.62	-0.15	0.53	0.3	0.08		0.71	0.32	0.51	-0.01	0.48	0.09	0.19	0.34	-0.49	0.49	-0.34	-0.27
Common Stock	0.69	0.23	0.64	-0.71	0.0	0.57	0.7	0.7	0.95	-0.28	0.13	0.17	0.22	0.71		0.25	0.1	-0.48	0.62	-0.06	0.4	0.05	-0.28	0.17	-0.22	-0.33
Short Long Term Debt Total	0.34	-0.32	0.39	-0.29	-0.66	0.09	0.3	0.31	0.19	0.61	0.53	0.75	-0.26	0.32	0.25		0.51	0.43	0.34	0.7	0.19	0.46	-0.53	0.41	0.12	0.43
Non Current Assets Total	0.55	0.0	0.53	-0.47	-0.5	0.47	0.49	0.5	-0.01	0.43	0.51	0.58	0.09	0.51	0.1	0.51		0.36	0.35	0.71	0.25	0.95	-0.57	0.96	-0.04	0.02
Non Currrent Assets Other	0.01	-0.22	0.05	0.03	-0.63	-0.18	-0.01	-0.01	-0.58	0.69	0.77	0.62	-0.18	-0.01	-0.48	0.43	0.36		-0.33	0.51	-0.42	0.27	-0.45	0.1	-0.2	0.69
Net Receivables	0.48	0.15	0.44	-0.46	0.03	0.29	0.46	0.46	0.63	-0.21	0.03	0.09	0.16	0.48	0.62	0.34	0.35	-0.33		-0.01	0.86	0.27	-0.01	0.46	0.08	-0.51
Non Current Liabilities Total	0.14	-0.19	0.16	-0.06	-0.75	0.14	0.08	0.09	-0.16	0.81	0.45	0.75	-0.1	0.09	-0.06	0.7	0.71	0.51	-0.01		-0.12	0.8	-0.59	0.61	-0.03	0.51
Inventory	0.2	0.27	0.13	-0.18	0.15	0.09	0.17	0.17	0.43	-0.31	-0.2	-0.12	0.27	0.19	0.4	0.19	0.25	-0.42	0.86	-0.12		0.19	0.21	0.4	0.38	-0.57
Property Plant And Equipment Gross	0.39	-0.01	0.37	-0.3	-0.54	0.44	0.33	0.33	-0.05	0.53	0.35	0.59	0.08	0.34	0.05	0.46	0.95	0.27	0.27	0.8	0.19		-0.55	0.93	-0.05	0.07
Other Current Liab	-0.51	0.35	-0.58	0.47	0.81	-0.48	-0.49	-0.49	-0.12	-0.65	-0.74	-0.88	0.31	-0.49	-0.28	-0.53	-0.57	-0.45	-0.01	-0.59	0.21	-0.55		-0.42	0.58	-0.5
Property Plant And Equipment Net	0.53	0.02	0.51	-0.46	-0.31	0.5	0.48	0.48	0.1	0.25	0.28	0.39	0.1	0.49	0.17	0.41	0.96	0.1	0.46	0.61	0.4	0.93	-0.42		0.07	-0.19
Current Deferred Revenue	-0.33	0.26	-0.39	0.33	0.33	-0.33	-0.34	-0.34	-0.12	-0.25	-0.45	-0.4	0.26	-0.34	-0.22	0.12	-0.04	-0.2	0.08	-0.03	0.38	-0.05	0.58	0.07		-0.2
Other Assets	-0.26	-0.32	-0.19	0.29	-0.75	-0.08	-0.27	-0.27	-0.41	0.77	0.51	0.65	-0.29	-0.27	-0.33	0.43	0.02	0.69	-0.51	0.51	-0.57	0.07	-0.5	-0.19	-0.2

Click cells to compare fundamentals

Organovo Holdings Account Relationship Matchups

Organovo Holdings fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	28.4M	39.9M	33.3M	20.3M	6.3M	6.0M
Total Current Liabilities	1.8M	721K	1.4M	3.7M	1.9M	3.3M
Total Stockholder Equity	26.6M	39.2M	30.2M	15.3M	3.6M	3.4M
Net Debt	(27.4M)	(37.4M)	(26.5M)	(13.5M)	(1.5M)	(1.6M)
Retained Earnings	(279.5M)	(296.3M)	(307.7M)	(325.0M)	(339.7M)	(322.7M)
Accounts Payable	720K	281K	415K	331K	627K	595.8K
Cash	27.4M	37.4M	28.7M	15.3M	2.9M	2.8M
Cash And Short Term Investments	27.4M	37.4M	28.7M	16.0M	2.9M	2.8M
Common Stock Total Equity	111K	124K	131K	9K	10.4K	9.8K
Common Stock Shares Outstanding	6.5M	6.9M	8.7M	8.7M	9.1M	6.1M
Liabilities And Stockholders Equity	28.4M	39.9M	33.3M	20.3M	6.3M	6.0M
Other Current Assets	851K	2.1M	1.7M	889K	705K	1.0M
Other Stockholder Equity	306.0M	335.5M	337.9M	340.3M	343.3M	242.2M
Total Liab	1.8M	721K	3.1M	5.0M	2.7M	3.7M
Total Current Assets	28.3M	38.4M	29.5M	17.0M	3.9M	3.7M
Common Stock	111K	124K	131K	9K	10K	9.5K
Non Current Assets Total	123K	1.5M	3.8M	3.3M	2.4M	2.4M
Non Currrent Assets Other	123K	1.1M	948K	658K	437K	413.2K
Net Receivables	558K	111K	0.0	152K	33K	31.4K
Non Current Liabilities Total	720K	281K	1.7M	1.3M	888K	664.9K
Property Plant And Equipment Gross	415K	381K	3.9M	3.9M	3.2M	2.4M
Other Current Liab	1.1M	440K	10K	2.4M	221K	210.0K
Property Plant And Equipment Net	0.0	381K	2.8M	2.6M	2.0M	2.2M
Intangible Assets	123K	109K	94K	13K	8K	7.6K
Net Tangible Assets	26.6M	39.1M	30.1M	15.3M	13.8M	13.1M
Net Invested Capital	26.6M	39.2M	30.2M	15.3M	3.6M	3.4M
Net Working Capital	26.5M	37.7M	28.2M	13.4M	2.1M	2.0M

Pair Trading with Organovo Holdings

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Organovo Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Organovo Holdings will appreciate offsetting losses from the drop in the long position's value.

Moving together with Organovo Stock

0.84	FDMT	4D Molecular Therapeutics	Pair Corr
0.81	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.84	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

Moving against Organovo Stock

0.85	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.74	NAMS	NewAmsterdam Pharma	Pair Corr
0.43	PHVS	Pharvaris BV	Pair Corr
0.39	PMVP	Pmv Pharmaceuticals	Pair Corr
0.36	ESLAW	Estrella Immunopharma	Pair Corr

The ability to find closely correlated positions to Organovo Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Organovo Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Organovo Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Organovo Holdings to buy it.

The correlation of Organovo Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Organovo Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Organovo Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Organovo Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Organovo Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organovo Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organovo Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organovo Holdings Stock:

How To Invest In Organovo

Details

Is Organovo Stock a good investment?

Details

What is Organovo Holdings' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organovo Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Organovo Stock, please use our How to Invest in Organovo Holdings guide.

You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organovo Holdings. If investors know Organovo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organovo Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.04)

Revenue Per Share

0.008

Quarterly Revenue Growth

(0.48)

Return On Assets

(0.89)

Return On Equity

(2.07)

The market value of Organovo Holdings is measured differently than its book value, which is the value of Organovo that is recorded on the company's balance sheet. Investors also form their own opinion of Organovo Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organovo Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organovo Holdings' market value can be influenced by many factors that don't directly affect Organovo Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Organovo Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organovo Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organovo Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Organovo Operating Income vs Research Development Analysis

Operating Income vs Research Development

Operating Income vs Research Development Correlation Analysis

Correlation Coefficient

Operating Income

Research Development

Organovo Holdings fundamental ratios Correlations

Organovo Holdings Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Organovo Holdings fundamental ratios Accounts

Pair Trading with Organovo Holdings

Moving together with Organovo Stock

Moving against Organovo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Net Debt	- 0.97	Total Stockholder Equity
Other Stockholder Equity	- 0.96	Retained Earnings